ArticleACS omega2022
Synthesis, Biological Evaluation, and Molecular Modeling Studies of 1-Aryl-1
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Synthesis, Photophysical Properties, and Primary Biological Characteristics of Meso-pyrazole-substituted BODIPY Derivatives.Journal of fluorescence · 2026Article
- Chemical constituents in the rhizome of Curcuma longa and the pharmacological importance of curcumin hybrids.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Boron Containing Curcumin-Like Compound as an Acetylcholinesterase Inhibitor and Anticancer Agent: Synthesis, Biological Evaluation, and Computational Insights.Cell biochemistry and biophysics · 2026Article
- Synthesis and CuPhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.Molecules (Basel, Switzerland) · 2026Review
- A Review of Research from 2012 to 2024 on Pyrazole-based Anticancer Agents with SAR Study.Current topics in medicinal chemistry · 2026Review
- Recent highlights in the synthesis and biological significance of pyrazole derivatives.Heliyon · 2024Review
- The untold story of starch as a catalyst for organic reactions.RSC advances · 2024Review
- Development of the Curcumin Analog CA7 Liposome and Its Evaluation for Efficacy Against Cervical Cancer in vitro and in vivo.International journal of nanomedicine · 2024Article
- Pyrazole Paradigms: Unveiling Synthetic Pathways and Unraveling Anti-Cancer Potential.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Synthesis,Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents.International journal of molecular sciences · 2023Review
- Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Addressing the growing burden of cancer and the shortcomings of chemotherapy in cancer treatment are the current research goals. Research to overcome the limitations of curcumin and to improve its anticancer activity via its heterocycle-fused monocarbonyl analogues (MACs) has immense potential. In this study, 32 asymmetric MACs fused with 1-aryl-1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.